Breathe BioMedical Launches Second Site in Its Multi-Center Clinical Trial of Its Breath Test for Breast Cancer
Moncton, New Brunswick and Cambridge, Massachusetts--(Newsfile Corp. - June 17, 2025) - Breathe BioMedical, a company developing a breath analytics platform for early disease detection, today announced the launch of the second site in its large multi-center observational collection protocol study to advance the development of its breath test for...
Technology, Biotechnology, Healthcare and Hospitals, Health
2025-06-17 7:00 AM EDT | Breathe BioMedical Inc.
Theralase(R) Closes Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - June 17, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses is pleased to announce that it has successfully closed a non-brokered private placement...
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2025-06-17 7:00 AM EDT | Theralase Technologies Inc.
PharmaDrug Announces Resignation of Rob Steen as CEO and From Board of Directors
Toronto, Ontario--(Newsfile Corp. - June 16, 2025) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs, is announcing that Rob Steen has resigned as...
Biotechnology, Cannabis, Psychedelics, Cannabis Manufacturer
2025-06-16 9:04 AM EDT | PharmaDrug Inc.
Sona Engages Clinical Trial Clinic for First-in-Human Early Feasibility Study of its THT Cancer Therapy
First Patients Expected to be Enrolled This MonthHalifax, Nova Scotia--(Newsfile Corp. - June 16, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") an oncology-focused life sciences company developing innovative therapies based on its uniquely biocompatible gold nanorod technology, today announced that it has entered into a...
2025-06-16 8:23 AM EDT | Sona Nanotech Inc.
InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPA
Vancouver, British Columbia--(Newsfile Corp. - June 13, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that Marcum LLP has resigned as InMed's auditor following the acquisition...
Biotechnology, Pharmaceuticals
2025-06-13 4:30 PM EDT | InMed Pharmaceuticals
Izotropic Provides Marketing Update
Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - June 13, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers, announces that it...
2025-06-13 8:00 AM EDT | Izotropic Corporation
Medicus Pharma Ltd. to Present at 2025 Bio International Convention
Philadelphia, Pennsylvania--(Newsfile Corp. - June 12, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce the schedule of the presentation of Dr. Raza Bokhari, Executive Chairman and CEO, at 2025 Bio International Convention.Event DetailsDate: Tuesday, June 17, 2025Time: 3:15 p.m. ETLocation: Room 153A, Boston...
Banking/Financial Services, Biotechnology, Investment Banking, Health
2025-06-12 7:30 AM EDT | Medicus Pharma Ltd.
Theralase Completes Annual General and Special Meeting
Toronto, Ontario--(Newsfile Corp. - June 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, is pleased to announce the successful completion of its Annual General and...
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2025-06-12 7:00 AM EDT | Theralase Technologies Inc.
PreveCeutical Announces Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - June 11, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce a non-brokered private placement (the "Offering") of up to 15,000,000 units in the capital of the Company (the "Units") at a price of $0.05 per Unit...
Biotechnology, Pharmaceuticals, Health
2025-06-11 5:19 PM EDT | PreveCeutical Medical Inc.
Biosenta's Tri-Filler(TM) Nanoparticles Achieve 100% Killing of Pathogens at Industry-Low Dose in Peer-Reviewed Studies
Toronto, Ontario and Calgary, Alberta--(Newsfile Corp. - June 11, 2025) - Biosenta Inc. (CSE: ZRO) ("Biosenta") today announced that two independent, peer-reviewed studies conducted at the University of Calgary confirmed that its proprietary Tri-Filler™ core-shell calcium hydroxide-calcium carbonate (CSCC™) nanoparticles achieved complete (100 %) bactericidal activity against multiple World Health Organization...
Biotechnology, Chemical, Household/Consumer/Cosmetics
2025-06-11 1:15 PM EDT | Biosenta Inc.
Maxwell Targets $500B Cosmetics Market with Microbiome-Friendly Antiseptics
Austin, Texas--(Newsfile Corp. - June 11, 2025) - Maxwell Biosciences, an innovator in technology that behaves like the natural immune system, announces its strategic entry into partnerships and licensing deals in the cosmetics and personal care market with its immune-inspired Claromer™ platform. The company's breakthrough Claromer™ technology is now being...
Biotechnology, Pharmaceuticals
2025-06-11 12:00 PM EDT | Maxwell Biosciences, Inc.
Restart Life Introduces BrainQ(TM) - A Wholly Owned Brand
Vancouver, British Columbia--(Newsfile Corp. - June 11, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to introduce BrainQ™, a wholly owned brand developed by the Company. The first product under the BrainQ™ brand will be the BrainQ™ Healthy...
Technology, Biotechnology, Health
2025-06-11 8:00 AM EDT | Restart Life Sciences Corp.
Therma Bright Inc. Announces Share Consolidation
Toronto, Ontario--(Newsfile Corp. - June 11, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma Bright" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, announces, subject to the approval of the TSX Venture Exchange (the "TSXV"), that it will...
Technology, Biotechnology, Health
2025-06-11 6:30 AM EDT | Therma Bright Inc.
Envoy Medical's Pivotal Clinical Trial for Fully Implanted Acclaim(R) Cochlear Implant Remains On Track After First Month Follow-Up
White Bear Lake, Minnesota--(Newsfile Corp. - June 10, 2025) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices that leverage the ear's natural anatomy, today announced that all 10 of the study participants in the first stage of the Company's...
Biotechnology, Healthcare and Hospitals
2025-06-10 8:30 AM EDT | Envoy Medical, Inc.
Izotropic Revises License Agreement with The Regents of the University of California
- License agreement enables U.S. FDA approval or foreign equivalent (CE mark) -- Amendment aligns with Company's timelines for IzoView product launch -- Agreement amendment fees of USD $85K payable in installments -Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - June 10, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF)...
2025-06-10 8:00 AM EDT | Izotropic Corporation
MustGrow and Phospholutions Sign Canadian Distribution Agreement for Phosphorous Efficiency Product - RhizoSorb(R)
Distribution agreement in Canada under MustGrow's sales and distribution division NexusBioAg. RhizoSorb® releases nutrients in the soil more efficiently to reduce phosphorus use by up to 50% while maximizing crop yield.Sustainable production and responsible use of phosphorus is critical to support global food demands.Saskatoon, Saskatchewan--(Newsfile Corp. - June 10, 2025)...
Agriculture, Biotechnology, Cannabis, Cannabis Breeder
2025-06-10 7:00 AM EDT | MustGrow Biologics Corp.
Medicus Pharma Ltd. Announces Submission of Product Development Plan to the Food and Drug Administration (FDA) to Treat External Squamous Cell Carcinoma (SCC) in Horses
Philadelphia, Pennsylvania--(Newsfile Corp. - June 9, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce submission of a comprehensive product development plan to treat external squamous cell carcinoma (SCC) under Investigational New Animal Drug (INAD File No.013880). The Company, in December 2024, received...
Banking/Financial Services, Biotechnology, Investment Banking, Health
2025-06-09 7:30 AM EDT | Medicus Pharma Ltd.
Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology
Montreal, Quebec--(Newsfile Corp. - June 9, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug delivery technologies, is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its U.S....
Biotechnology, Pharmaceuticals, Health
2025-06-09 3:15 AM EDT | Defence Therapeutics Inc.
PharmaDrug Announces Strategic Review Process Intended to Maximize Shareholder Value
Toronto, Ontario--(Newsfile Corp. - June 6, 2025) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs, is announcing that the board of directors ("the...
Biotechnology, Cannabis, Psychedelics, Cannabis Manufacturer
2025-06-06 8:00 AM EDT | PharmaDrug Inc.
Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio
- Robert Infarinato named VP, Strategic Development- Lisa Carson named as new VP, Finance and AdministrationMarlborough, Massachusetts--(Newsfile Corp. - June 6, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to treat cancer. Phio announced today a...
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-06-06 7:45 AM EDT | Phio Pharmaceuticals Corp.